Vancomycin

New England Life Care Selects DoseMe to Support New Initiatives Around Compliance Protocols

Retrieved on: 
Jeudi, août 3, 2023
Nursing, Health, Hospitals, Health Technology, General Health, Pharmaceutical, Society, Nephrotoxicity, Infection, Society of Infectious Diseases Pharmacists, IDSA, CCO, Aminoglycoside, Hospital, Vancomycin, NELC, American Society of Health-System Pharmacists, Patient, Patient safety, AUC, Medicine, PIDS, Infectious Diseases Society of America, ASHP, TDM, Software, Medical device, Pharmacy, Dosem

New England Life Care is nationally recognized as a nonprofit, mission-driven home infusion therapy and specialty pharmacy services provider affiliated with 60+ of New England’s premier medical centers.

Key Points: 
  • New England Life Care is nationally recognized as a nonprofit, mission-driven home infusion therapy and specialty pharmacy services provider affiliated with 60+ of New England’s premier medical centers.
  • “As a home infusion pharmacy, NELC wanted to make sure we were prepared to support our member hospitals when instituting new procedures and protocols related to the new vancomycin guidelines, released in 2020,” stated Erica Sievert, Regional Director of Pharmacy for New England Life Care.
  • New England Life Care is using DoseMeRx’s clinical decision support software to dose vancomycin and aminoglycosides.
  • “We are thrilled to be working with the team at New England Life Care to better serve their patients while staying ahead of guidelines and protocols,” said John Hardesky, CCO of DoseMe.

DRESS Smarter: Bridging the Gap in Severe Drug Reactions

Retrieved on: 
Mercredi, juillet 12, 2023
Knowledge, Hypersensitivity, Eosinophilia, Ohio State University, Disulfiram-like drug, Vancomycin, Heart, Anticonvulsant, Education, World Down Syndrome Day, Smarter Sentencing Act, Fever, Trimethoprim/sulfamethoxazole, Human, Research, Drug reaction with eosinophilia and systemic symptoms, Allopurinol, Rash, Plasma protein binding, DRESS, Patient, Physician, Risk, Ohio State University Wexner Medical Center, REDRESS, Liver, Diagnosis, Health, Recurrence, Lymphadenopathy, Residential care, Pharmaceutical industry, Nursing, Medical device, Vaccine, Lamotrigine

RICHMOND, Va., July 12, 2023 /PRNewswire-PRWeb/ -- Around the world, millions of people suffer from severe adverse drug reactions, many of which do not get proper funding or research. For patients with DRESS Syndrome, the experience can be isolating. However, a nonprofit behind National DRESS Syndrome Day is providing a platform for building awareness of this debilitating life threatening condition. On July 16, 2023, the DRESS Syndrome Foundation will encourage patients and medical communities to unite over this year's theme: "DRESS/smarter." By recognizing positive advancements in DRESS Syndrome, the holiday gives a voice to this uncommon but life-threatening reaction, and supports research efforts that bridge the gap worldwide.

Key Points: 
  • A national holiday with a global reach, DRESS Syndrome Day highlights progress and future insights into severe adverse drug reactions.
  • "There is still so much we don't understand about this severe and potentially fatal drug reaction," explains Tasha Tolliver, Executive Director and Co-Founder of DRESS Syndrome Foundation.
  • Additionally, Dr. Korman's team identified a unique "earlobe crease sign" that distinguishes DRESS from other severe adverse drug reactions, facilitating faster and more accurate diagnosis.
  • "We founded the DRESS Syndrome Foundation to fill a much-needed gap in patient advocacy, a gap that today would have saved our daughters lives," says Nancy Szakacsy, Co-Founder of DRESS Syndrome Foundation.

PrecisePK Establishes a New Standard of Care in Spain with Hospital Universitari Mutua Terrassa

Retrieved on: 
Jeudi, juin 15, 2023
Partnership, Doctor of Pharmacy, Therapeutic drug monitoring, Pharmacokinetics, Research, Pharmacist, Hospital, Vancomycin, SAN, AUC, Medicine, Patient, Health, TDM, Software, Nursing, Medical imaging

PrecisePK and Hospital Universitari Mutua Terrassa advance clinical pharmacokinetics in Spain with Bayesian dosing.

Key Points: 
  • PrecisePK and Hospital Universitari Mutua Terrassa advance clinical pharmacokinetics in Spain with Bayesian dosing.
  • Genís Castells, PharmD, an experienced hospital pharmacist leading TDM at Hospital Universitari Mutua Terrassa, expressed his satisfaction with the partnership.
  • "We are delighted to partner with Hospital Universitari Mutua Terrassa and contribute to their mission of delivering exceptional patient care," says Katherine Ninh, Operations and Accounts Manager at PrecisePK.
  • The collaboration between PrecisePK and Hospital Universitari Mutua Terrassa exemplifies the country's commitment to advancing the field of precision medicine and sets a precedent for other healthcare institutions to follow.

Kern Medical Chooses PrecisePK to Provide Bayesian Precision Dosing Solutions

Retrieved on: 
Jeudi, mai 25, 2023
BCPS, Society, Infectious Diseases Society of America, MIC, Doctor of Pharmacy, Partnership, Kern Medical Center, Staphylococcus, OPAT, Education, Workflow, Society of Infectious Diseases Pharmacists, Infection, ID, Pharmacist, Vancomycin, Patient, SAN, Microsoft Excel, AUC, Knowledge, UCLA, American Society of Health-System Pharmacists, Pharmaceutical industry, List of things named after Thomas Bayes

SAN DIEGO, May 25, 2023 /PRNewswire/ -- Today, PrecisePK welcomes Kern Medical as its latest institution to implement innovations in precision dosing for vancomycin and other antibiotics using the Bayesian AUC-based method.

Key Points: 
  • SAN DIEGO, May 25, 2023 /PRNewswire/ -- Today, PrecisePK welcomes Kern Medical as its latest institution to implement innovations in precision dosing for vancomycin and other antibiotics using the Bayesian AUC-based method.
  • This recent alliance with Kern Medical adds to the system-wide endeavor of accomplishing personalized and precision dosing with a modernized approach by leveraging technology.
  • Kern Medical's vancomycin dosing workflow is standardized and improved by PrecisePK's Bayesian precision dosing tools.
  • With Bayesian precision dosing, it's more than the right dose for the right patient at the right time.

STIMULAN now available in South Africa to treat bacterial infection

Retrieved on: 
Mercredi, mai 10, 2023
Infection, Surgeon, University, Freedom, University of Cape Town, Genex Power, Doctor of Philosophy, Associate, Hospital, Vancomycin, Patient, Division, Neoplasm, Orthopedic surgery, Genetically modified bacteria, Tobramycin, Stellenbosch University, Pharmaceutical industry, EU, Sepsis

KEELE, England, May 10, 2023 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces that its STIMULAN® products are now available in South Africa for treating bacterial infection.

Key Points: 
  • KEELE, England, May 10, 2023 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces that its STIMULAN® products are now available in South Africa for treating bacterial infection.
  • South Africa now joins a growing list of countries, which include the UK, EU, Canada, Mexico and Saudi Arabia where STIMULAN can carry antibiotics, such as vancomycin, gentamicin and tobramycin to a site of infection.
  • STIMULAN is the first and only approved calcium matrix that can carry antibiotics to treat bacterial infection and is now used in over 80,000 procedures every year, in thousands of hospitals around the world.
  • Nando Fereira, PhD, Full Professor and Head of Clinical Unit (Tumour, Sepsis, and Reconstruction) at Stellenbosch University added: "I am excited to learn that STIMULAN will soon be available in South Africa through Novus Healthcare.

STIMULAN now available in South Africa to treat bacterial infection

Retrieved on: 
Mercredi, mai 10, 2023
Infection, Surgeon, University, Freedom, University of Cape Town, Genex Power, Doctor of Philosophy, Associate, Hospital, Vancomycin, Patient, Division, Neoplasm, Orthopedic surgery, Genetically modified bacteria, Tobramycin, Stellenbosch University, Pharmaceutical industry, EU, Sepsis

KEELE, England, May 10, 2023 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces that its STIMULAN® products are now available in South Africa for treating bacterial infection.

Key Points: 
  • KEELE, England, May 10, 2023 /PRNewswire/ -- Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces that its STIMULAN® products are now available in South Africa for treating bacterial infection.
  • South Africa now joins a growing list of countries, which include the UK, EU, Canada, Mexico and Saudi Arabia where STIMULAN can carry antibiotics, such as vancomycin, gentamicin and tobramycin to a site of infection.
  • STIMULAN is the first and only approved calcium matrix that can carry antibiotics to treat bacterial infection and is now used in over 80,000 procedures every year, in thousands of hospitals around the world.
  • Nando Fereira, PhD, Full Professor and Head of Clinical Unit (Tumour, Sepsis, and Reconstruction) at Stellenbosch University added: "I am excited to learn that STIMULAN will soon be available in South Africa through Novus Healthcare.

Scandinavia's Largest Hospital Becomes Second Institution in Norway to Adopt PrecisePK's Bayesian Dosing Software

Retrieved on: 
Vendredi, mai 5, 2023
Oslo University Hospital, Partnership, Tacrolimus, University, Patient, UNN, Research, Department of Psychology, University of Oslo, Disulfiram-like drug, Teaching hospital, Aminoglycoside, Vancomycin, Patient safety, SAN, AUC, Busulfan, OUS, University Hospital of North Norway, TDM, Pharmaceutical industry

SAN DIEGO, May 3, 2023 /PRNewswire/ -- Today, PrecisePK announces that it will begin partnering with Oslo University Hospital (OUS) in Norway.

Key Points: 
  • SAN DIEGO, May 3, 2023 /PRNewswire/ -- Today, PrecisePK announces that it will begin partnering with Oslo University Hospital (OUS) in Norway.
  • PrecisePK is delighted to welcome OUS on board as its second Norwegian health institution, following the University Hospital of North Norway (UNN).
  • Oslo University Hospital modernizes its technology used for patient-centered care with PrecisePK's Bayesian MIPD.
  • In 2021, UNN's system-wide implementation of Bayesian AUC dosing for vancomycin and busulfan was a resounding success.

Scandinavia's Largest Hospital Becomes Second Institution in Norway to Adopt PrecisePK's Bayesian Dosing Software

Retrieved on: 
Mercredi, mai 3, 2023
Oslo University Hospital, Partnership, Tacrolimus, University, Patient, UNN, Research, Department of Psychology, University of Oslo, Disulfiram-like drug, Teaching hospital, Aminoglycoside, Vancomycin, Patient safety, SAN, AUC, Busulfan, OUS, University Hospital of North Norway, TDM, Pharmaceutical industry

SAN DIEGO, May 3, 2023 /PRNewswire/ -- Today, PrecisePK announces that it will begin partnering with Oslo University Hospital (OUS) in Norway.

Key Points: 
  • SAN DIEGO, May 3, 2023 /PRNewswire/ -- Today, PrecisePK announces that it will begin partnering with Oslo University Hospital (OUS) in Norway.
  • PrecisePK is delighted to welcome OUS on board as its second Norwegian health institution, following the University Hospital of North Norway (UNN).
  • Oslo University Hospital modernizes its technology used for patient-centered care with PrecisePK's Bayesian MIPD.
  • In 2021, UNN's system-wide implementation of Bayesian AUC dosing for vancomycin and busulfan was a resounding success.

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

Retrieved on: 
Mercredi, avril 19, 2023
ISLAND, VRE, Clostridioides difficile infection, DNA, DNA-binding protein, University, IV, Flagellum, Public, IIIC, MRSA, Infection, Genetically modified bacteria, Houston Community College, Solubility, DRSP, Movement, Congress, Professor, ECCMID, Vancomycin, European, Metronidazole, University of Houston, Fidaxomicin, Susceptibility, Poster, Principal, Pharmacology, Recurrence, Virulence, Safety, Microbiology, Vaccine, Pharmacy

C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.

Key Points: 
  • C. difficile strains with reduced susceptibility to metronidazole, vancomycin, or fidaxomicin were susceptible to ibezapolstat, confirming its unique mechanism of action.
  • To study anti-virulence effect, our group investigated an under-studied virulence property of C difficile, namely, flagellar movement of the organism.
  • All of these positive and unexpected findings reflect the unique mode of action in inhibiting DNA pol IIIC and support the continued development of ibezapolstat to treat C. difficile infection."
  • The poster and presentation are available on the Company's website www.acurxpharma.com.

New shape-shifting antibiotics could fight deadly infections

Retrieved on: 
Mardi, avril 4, 2023
Infection, Weapon, VRE, University, Life, Bullvalene, Survival, MRSA, Skin, Fungus, Cold, University of Adelaide, SPRING, Click chemistry, Vancomycin, CSHL, Nobel, Bacteria, Cold Spring Harbor Laboratory, VRSA, Death, Environment, Meningitis, World Health Organization, Antibiotics

Antibiotics are essential and effective, but in recent years overuse has led to some bacteria developing resistance to them.

Key Points: 
  • Antibiotics are essential and effective, but in recent years overuse has led to some bacteria developing resistance to them.
  • The infections are so difficult to treat, the World Health Organization deemed antibiotic resistance a top 10 global public health threat.
  • Moses came up with the idea of shape-shifting antibiotics while observing tanks in military training exercises.
  • The researchers gave the drug to VRE-infected wax moth larvae, which are commonly used to test antibiotics.